0001654954-19-006335.txt : 20190520 0001654954-19-006335.hdr.sgml : 20190520 20190520161814 ACCESSION NUMBER: 0001654954-19-006335 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190520 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20190520 DATE AS OF CHANGE: 20190520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 19838984 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 8-K 1 cvm_8k.htm CURRENT REPORT Blueprint
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): May 20, 2019
 
CEL-SCI CORPORATION
(Exact name of Registrant as specified in its charter)
 
 Colorado
 01-11889
 84-0916344
 (State or other jurisdiction of incorporation)
 (Commission File No.)
 (IRS Employer Identification No.)
 
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
(Address of principal executive offices, including Zip Code)
 
Registrant’s telephone number, including area code:      (703) 506-9460
 
N/A
(Former name or former address if changed since last report)
  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter.
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
CVM
NYSE American
 

 
 
 
Item 5.07.  Submission of Matters to a Vote of Securities Holders.
 
The annual meeting of CEL-SCI’s shareholders was held on May 20, 2019. At the meeting the following persons were elected as directors for the upcoming year:
 
 
 
Votes
 
 
Broker
 
Name
 
For
 
 
Against
 
 
Non-Votes
 
 
 
 
 
 
 
 
 
 
 
Geert R. Kersten
  8,412,320 
  414,263 
  13,580,049 
Peter R. Young
  8,379,723 
  446,860 
  13,580,049 
Bruno Baillavoine
  8,486,037 
  340,546 
  13,580,049 
Robert Watson
  8,452,841 
  373,742 
  13,580,049 
At the meeting the following were approved by CEL-SCI’s shareholders:
 
(1)
the adoption of CEL-SCI’s 2019 Non-Qualified Stock Option Plan which provides that up to 3,000,000 shares of common stock may be issued upon the exercise of options granted pursuant to the Plan;
 
(2)
the adoption of CEL-SCI’s 2019 Stock Compensation Plan which provides that up to 500,000  shares of common stock may be issued pursuant to the Plan; and
 
(3)
the appointment of BDO USA, LLP as CEL-SCI’s independent registered public accounting firm for the fiscal year ending September 30, 2019.
 
The following is a tabulation of votes cast with respect to proposals 1, 2, and 3:
 
 
 
Votes
 
 
Broker
 
Proposal
 
For
 
 
Against
 
 
Abstain
 
 
Non-Votes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1)
  6,871,004 
  1,896,529 
  59,050 
  13,580,049 
(2)
  7,254,753 
  1,501,925 
  69,905 
  13,580,049 
(3)
  22,189,280 
  145,861 
  71,491 
  - 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
CEL-SCI CORPORATION
 
 
 
 
 
Date: May 20, 2019
By:  
/s/ Patricia B. Prichep
 
 
 
Patricia B. Prichep 
 
 
 
Senior Vice President of Operations